icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
SenqjPgHDEQ2RA2U
Listen
